Pan American Health Organization

Human Papillomavirus Vaccine Research Report 2023: Highly Effective HPV Vaccines Target Major Cancer-Causing Strains - Global Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 12, 2023
Infectious Diseases, Pharmaceutical, Health, Vaccine, The central science, Infection, Anal cancer, Prevalence, Vagina, PAHO, Pharynx, Human papillomavirus infection, Vulvar cancer, Woman, Research, UNICEF, Pan American Health Organization, Government, Competition, CDC, Organization, Market, Death, Cervical cancer, Developed country, Korea Disease Control and Prevention Agency, HPV, Growth, WHO

According to clinical trials.gov, as of November 2022, around 394 clinical studies are in different phases of development related to human papillomavirus vaccines across the globe.

Key Points: 
  • According to clinical trials.gov, as of November 2022, around 394 clinical studies are in different phases of development related to human papillomavirus vaccines across the globe.
  • Upsurge in the cases of Human Papillomavirus related diseases in different organs such as the anal, oropharynx, and genital parts has significantly raised the demand for Human Papillomavirus vaccines, thereby creating lucrative opportunities for market growth.
  • This has, in turn, increased the research and development activities and products launched related to human papillomavirus vaccine.
  • For instance, recently, India launched the first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer.

Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review

Retrieved on: 
Tuesday, August 29, 2023
Epidemic, Priority review, NDS, Biologics license application, Pan American Health Organization, Saint-Herblain, Priority, Marketing, Coalition, European Medicines Agency, Valneva SE, CEPI, PAHO, Coalition for Epidemic Preparedness Innovations, Licensure, Chikungunya, Person, Trial of the century, Fast track (FDA), EMA, Euronext Paris, VLA, MD, Instituto Butantan, Ageing, FDA, Health Canada, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Pharmaceutical industry, Vaccine, Lancet

Based on Health Canada’s performance standard to process an NDS application, the Company believes the regulatory review could be completed by mid-2024.

Key Points: 
  • Based on Health Canada’s performance standard to process an NDS application, the Company believes the regulatory review could be completed by mid-2024.
  • This is the second regulatory application for VLA1553 filed by Valneva, and the Company intends to make additional regulatory submissions in 2023.
  • A Biologic License Application (BLA) is currently under priority review1 by the U.S. Food and Drug Administration (FDA)2.
  • VLA1553 is currently the only chikungunya vaccine candidate worldwide for which regulatory review processes are underway and, if approved, it could become the first licensed chikungunya vaccine available to address this unmet medical need.

KORE Supports GrandPad Mission to Help Seniors Age in Place with IoT

Retrieved on: 
Thursday, August 3, 2023
Cognition, Good, Internet of things, PAHO, KORE, Long-term care, Ageing, Pan American Health Organization, Internet, Frasier, GrandPad, Hearing, System, CO, Family, Caregiver, Customer service, Management, Nursing

ATLANTA, Aug. 3, 2023 /PRNewswire/ -- KORE, a global leader in Internet of Things ("IoT") Solutions and pioneering IoT hyperscaler, and provider of IoT Connectivity, Solutions and Analytics, announced today its alliance with GrandPad, a revolutionary service that allows seniors to connect with loved ones and caregivers at the touch of a button.

Key Points: 
  • A key piece of aging in place is connecting seniors to family and caregivers simply and affordably, which is where KORE's relationship with GrandPad comes into play.
  • Powered by KORE's robust IoT connectivity solutions, GrandPad is an easy-to-use communication device allowing seniors to connect to vital caregivers and family members by making video calls, sending voice messages, and viewing media.
  • Romil Bahl, KORE President and CEO, said KORE is honored to provide its extensive IoT technology to help seniors age with grace and dignity.
  • To learn more about GrandPad and KORE's "IoT for Good" initiative, read the full case study here .

Healthcare Information Systems Industry Expected to Grow at CAGR of 13.3% from 2023 to 2030 - Grand View Research, Inc.

Retrieved on: 
Wednesday, July 12, 2023
Informatics, IHI, Telehealth, SingHealth, Hospital, CMS, Information, Office of Inspector General, U.S. Department of Health and Human Services, HHS, DME, Health, Big data, Pharmacy, Workflow, Patient satisfaction, RFID, Sunrise, COVID-19, RCM, Kaiser Family Foundation, Intelligence, Medicine, Automation, USD, Pan American Health Organization, Integrated Health Information Systems, HIS, Government, Singapore General Hospital, Investment, EHR, Patient safety, Laboratory, SAN, AI, R, Kids Count Data Book, Pharmaceutical industry

SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- The global healthcare information systems industry size reached USD 406.4 billion in 2022 and will exhibit a CAGR of 13.3% from 2023 to 2030, according to the " Healthcare Information Systems Industry Data Book, 2023 - 2030 ," published by Grand View Research.

Key Points: 
  • SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- The global healthcare information systems industry size reached USD 406.4 billion in 2022 and will exhibit a CAGR of 13.3% from 2023 to 2030, according to the " Healthcare Information Systems Industry Data Book, 2023 - 2030 ," published by Grand View Research.
  • Pan American Health Organization notes that around 30,000 paper-based files will be converted to electronic medical records—largely attributed to health information systems (HIS).
  • An uptick in implementing digital health, electronic health record (EHR) and durable medical equipment (DME) have accentuated the demand for hospital information systems.
  • The global hospital information system market size garnered USD 118.2 billion in 2022 and could witness a robust CAGR of 17.7% through 2030.

Healthcare Information Systems Industry Expected to Grow at CAGR of 13.3% from 2023 to 2030 - Grand View Research, Inc.

Retrieved on: 
Wednesday, July 12, 2023
Informatics, IHI, Telehealth, SingHealth, Hospital, CMS, Information, Office of Inspector General, U.S. Department of Health and Human Services, HHS, DME, Health, Big data, Pharmacy, Workflow, Patient satisfaction, RFID, Sunrise, COVID-19, RCM, Kaiser Family Foundation, Intelligence, Medicine, Automation, USD, Pan American Health Organization, Integrated Health Information Systems, HIS, Government, Singapore General Hospital, Investment, EHR, Patient safety, Laboratory, SAN, AI, R, Kids Count Data Book, Pharmaceutical industry

SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- The global healthcare information systems industry size reached USD 406.4 billion in 2022 and will exhibit a CAGR of 13.3% from 2023 to 2030, according to the " Healthcare Information Systems Industry Data Book, 2023 - 2030 ," published by Grand View Research.

Key Points: 
  • SAN FRANCISCO, July 12, 2023 /PRNewswire/ -- The global healthcare information systems industry size reached USD 406.4 billion in 2022 and will exhibit a CAGR of 13.3% from 2023 to 2030, according to the " Healthcare Information Systems Industry Data Book, 2023 - 2030 ," published by Grand View Research.
  • Pan American Health Organization notes that around 30,000 paper-based files will be converted to electronic medical records—largely attributed to health information systems (HIS).
  • An uptick in implementing digital health, electronic health record (EHR) and durable medical equipment (DME) have accentuated the demand for hospital information systems.
  • The global hospital information system market size garnered USD 118.2 billion in 2022 and could witness a robust CAGR of 17.7% through 2030.

After a decades-long fight against malaria, Belize is certified malaria-free by the World Health Organization

Retrieved on: 
Wednesday, June 21, 2023
Our Lady, Queen of the Americas (Washington, D.C.), Volunteering, Sustainable Development Goal 3, Tuberculosis, Inter-American Development Bank, Community, The Global Fund to Fight AIDS, Tuberculosis and Malaria, PAHO, United Nations Foundation, Pan American Health Organization, Bill & Melinda Gates Foundation, Movement, Government, International development, Death, UN, Sustainable Development Goals, Bill, Diagnosis, Pregnancy, WHO, Health, World Health Organization, Disease, Vaccine, Malaria, United

WASHINGTON, June 21, 2023 /PRNewswire-PRWeb/ -- The World Health Organization (WHO) has certified Belize for achieving malaria elimination, a significant milestone more than 70 years in the making. Belize becomes the second Central American country, after El Salvador, and 42nd country (plus one territory) worldwide to receive malaria-free certification.

Key Points: 
  • Belize becomes the second Central American country, after El Salvador, and 42nd country (plus one territory) worldwide to receive malaria-free certification.
  • "Belize is the latest success story in the decades-long global fight to end malaria," said United Nations Foundation President and CEO Elizabeth Cousens.
  • "This milestone is a testament to the power of sustained government commitment and strategic partnerships across borders, sectors, and communities.
  • The Pan American Health Organization (PAHO), a longtime technical partner, has helped the Belize government build its capacity for prompt malaria diagnosis, treatment, and surveillance.

Valneva Files for Chikungunya Vaccine Authorization with Health Canada

Retrieved on: 
Tuesday, May 30, 2023
Epidemic, Biologics license application, Pan American Health Organization, Saint-Herblain, Vaccination, Priority, Coalition, European Medicines Agency, Valneva SE, CEPI, PAHO, Coalition for Epidemic Preparedness Innovations, Licensure, Chikungunya, Person, Trial of the century, Fast track (FDA), EMA, Euronext Paris, VLA, MD, Instituto Butantan, PDUFA, Ageing, FDA, Health Canada, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Pharmaceutical industry, Vaccine

Saint-Herblain (France), May 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the filing of a regulatory application with Health Canada for marketing approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553, in persons aged 18 years and above.

Key Points: 
  • Saint-Herblain (France), May 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the filing of a regulatory application with Health Canada for marketing approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553, in persons aged 18 years and above.
  • If accepted, Health Canada will provide additional information on the potential approval timeline.
  • This is the second regulatory application for VLA1553 filed by Valneva, and the Company intends to make additional regulatory submissions in 2023.
  • VLA1553 is currently the only chikungunya vaccine candidate worldwide for which regulatory review processes are underway and, if approved, it could become the first licensed chikungunya vaccine available to address this unmet medical need.

SK bioscience Presents Solution for Equitable Access of Vaccine at Regionalized Vaccine Manufacturing Collaborative of World Economic Forum

Retrieved on: 
Tuesday, May 23, 2023
Epidemic, Coalition for Epidemic Preparedness Innovations, Pan American Health Organization, SK, Multilateralism, WEF, Glocalization, Coalition, PAHO, CEPI, World Health Assembly, COVID-19, GAVI, African Center for Economic Transformation, Messenger, RVMC, Rochester Regional Health, Gavi, WHO, Vaccine, Ahn, World Health Organization, Pharmaceutical industry, Security (finance), Immunization, Health

Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event.

Key Points: 
  • Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event.
  • The RVMC is a global initiative launched at the World Economic Forum (WEF) in May 2022 to address inequality in vaccine distribution between few rich countries and low- and middle-income countries during the COVID-19 pandemic.
  • SK bioscience came up with a regional-based vaccine hub as a business model during the COVID-19 pandemic when inequality in COVID-19 vaccine distribution was exposed.
  • Currently, SK bioscience is preparing to establish the regional vaccine hubs in the Middle East, Africa, Southeast Asia, and Latin America.

AHF and PAHO Make Partnership Official

Retrieved on: 
Wednesday, May 3, 2023
Infectious Diseases, AIDS, Health, Healthcare Reform, Public Policy, Government, AHF, HIV/AIDS, Partnership, PAHO, Hurricane Matthew, Multimedia, Infection, Pan American Health Organization, Organization, Amazon, Viral, Tuberculosis, AIDS Healthcare Foundation, Drug

AIDS Healthcare Foundation (AHF) and the Pan American Health Organization (PAHO) met in Washington D.C. earlier this week, where the organizations entered into an official partnership to fight HIV/AIDS, other sexually transmitted infections, and other conditions, including tuberculosis, hepatitis viruses, and mpox.

Key Points: 
  • AIDS Healthcare Foundation (AHF) and the Pan American Health Organization (PAHO) met in Washington D.C. earlier this week, where the organizations entered into an official partnership to fight HIV/AIDS, other sexually transmitted infections, and other conditions, including tuberculosis, hepatitis viruses, and mpox.
  • View the full release here: https://www.businesswire.com/news/home/20230503005922/en/
    PAHO Director Dr. Jarbas Barbosa (left) with AHF President Michael Weinstein.
  • AHF has worked in Latin America and the Caribbean since 2006 and provides HIV/AIDS care and treatment to more than 228,000 clients in 12 countries in the region.
  • Additionally, AHF has provided humanitarian relief during natural disasters and other crises, including Hurricane Matthew in 2016 and the 2021 earthquake in Haiti and the refugee crisis along the Colombia-Venezuela border .

GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea

Retrieved on: 
Thursday, February 9, 2023
CMO, Vaccine, Pan American Health Organization, Pan-American, World Health Organization, Certification, WHO, Yellow Pills: Prefill, EC, Approved Drug Products with Therapeutic Equivalence Evaluations, Public, PQ, COVID-19, PAHO, UNICEF

YONGIN, South Korea, Feb. 8, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that the World Health Organization (WHO) has awarded prequalification to filling and finish plant on February 3 2023, located in Ochang, South Korea.

Key Points: 
  • YONGIN, South Korea, Feb. 8, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that the World Health Organization (WHO) has awarded prequalification to filling and finish plant on February 3 2023, located in Ochang, South Korea.
  • This plant is the largest filling and finish facility based in South Korea, established in 2019.
  • GC Biopharma can produce 300 million doses annually here, enabling CMO of Drug Products (DP) for vaccines (Sterile vials and Prefilled syringe) and non-vaccine filling & finish and packaging.
  • Based on this PQ certification, GC Biopharma has established a global-level production hub that can manufacture the products at the global standards, to this facility following a vaccine plant located in Hwa-sun, South Korea.